Showing results (441-450 of 548) with videos related to
Sort By:
Pageof 55
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2003
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro propertiesJosette Carnahan, Paul Wang, Richard Kendall, et al.Journal of Immunology (Baltimore, Md. : 1950)|February 5, 2000
Cutting edge: identification of GL50, a novel B7-like protein that functionally binds to ICOS receptorV Ling, P W Wu, H F Finnerty, et al.Journal of the National Cancer Institute|December 18, 2016
Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma ResearchGrzegorz S Nowakowski, Kristie A Blum, Brad S Kahl, et al.British Journal of Haematology|August 10, 2007
Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naïve patients undergoing front-line lenalidomide and dexamethasone therapyRuben Niesvizky, Tara Naib, Paul J Christos, et al.AMIA Joint Summits on Translational Science Proceedings. AMIA Joint Summits on Translational Science|July 2, 2019
Evaluation of a REDCap-based Workflow for Supporting Federal Guidance for Electronic Informed ConsentCindy Chen, Scott P Turner, Evan T Sholle, et al.Bioinformatics (Oxford, England)|June 21, 2024
GENTANGLE: integrated computational design of gene entanglementsJose Manuel Martí, Chloe Hsu, Charlotte Rochereau, et al.Journal of Geriatric Oncology|April 21, 2018
Frequency and impact of grade three or four toxicities of novel agents on outcomes of older patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma (alliance A151611)Michael Tallarico, Jared C Foster, Drew Seisler, et al.Blood|January 18, 2011
The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphomaJonathan W Friedberg, Julie M Vose, Jennifer L Kelly, et al.Journal of the National Cancer Institute|January 2, 2017
Recommendations for Clinical Trial Development in Mantle Cell LymphomaStephen E Spurgeon, Brian G Till, Peter Martin, et al.Blood|September 6, 2018
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphomaJia Ruan, Peter Martin, Paul Christos, et al.Pageof 55